Young Investigators awarded $200k to study innovative new ways to engage the body’s immune system to fight lung cancer
17 janv. 2022 08h15 HE | Lung Cancer Foundation of America
Los Angeles, CA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Two new $200,000 grant-funded studies supported by the Lung Cancer Foundation of America, the International Lung Cancer Foundation, and generously...
22157.jpg
Worldwide Immuno Oncology Assays Industry to 2026 - Clinical Trials to Cure Different Cancers in Immunotherapy Presents Opportunities
05 janv. 2022 06h38 HE | Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Immuno Oncology Assays Market Research Report by Indication, Product, Technology, Application, and Region - Global Forecast to 2026 - Cumulative Impact...
anpac_logo_full color_stacked.png
AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022
04 janv. 2022 07h30 HE | AnPac Bio-Medical Science Co., Ltd.
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a US and China-based biotechnology company focused on early cancer...
CO-MasterLogo@4x_300 DPI.png
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
04 janv. 2022 07h00 HE | Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
16 déc. 2021 06h30 HE | Cullinan Oncology, Inc.
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in...
Coherus BioSciences, Inc. logo
Coherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
13 déc. 2021 07h00 HE | Coherus BioSciences, Inc.
SHANGHAI, China and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences,...
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
13 déc. 2021 07h00 HE | Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
22157.jpg
Global Interventional Oncology Devices Market, 2021-2030: Opportunities in the Emergence of Local Companies in Asia-Pacific and the Middle East and Africa
06 déc. 2021 06h43 HE | Research and Markets
Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Market Analysis and Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering. The global...
Persbericht Biocartis Group NV: Nieuwe studie toont aan dat Idylla™ EGFR Mutation Test (CE-IVD) de tijd tot beslissingen inzake patiëntenbeheer inkort voor patiënten met niet-kleincellige longkanker
16 nov. 2021 01h00 HE | Biocartis NV
PERSBERICHT: 16 november 2021, 07:00 CET Nieuwe studie toont aan dat Idylla™ EGFR Mutation Test (CE-IVD) de tijd tot beslissingen inzake patiëntenbeheer inkort voor patiënten met niet-kleincellige...
Press release Biocartis Group NV: New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens Time to Patient Management Decisions for Patients with Non-Small Cell Lung Cancer
16 nov. 2021 01h00 HE | Biocartis NV
PRESS RELEASE: 16 November 2021, 07:00 CET New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens Time to Patient Management Decisions for Patients with Non-Small Cell Lung Cancer ...